GigaGen to Present Novel Antibody Development and T Cell Discovery Methods at 2018 Keystone Symposia Conferences
SOUTH SAN FRANCISCO, Feb. 12, 2018 /PRNewswire/ -- GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, will be presenting the findings of its research on novel approaches to antibody development and T cell discovery for diseases of immune dysregulation at two upcoming Keystone Symposia conferences. The first conference, "Emerging Cellular Therapies: T Cells and Beyond," will take place Feb. 11-15 in Keystone, Colo., and the second, "Antibodies as Drugs: Translating Molecules into Treatments," will be held Feb. 25-March 1 in Whistler, British Columbia.
Matthew Spindler, Ph.D., Director of T Cell Engineering at GigaGen, will present poster #3012, titled "Discovery of Potent Anti-Tumor TCRs in Recombinant TCR Libraries Generated from Tumor Infiltrating Lymphocytes," from 7:30-10 p.m. MST on Wednesday, Feb. 14, at Keystone Resort in Keystone, Colo.
Adam Adler, Ph.D., Vice President of Research and Development at GigaGen, will present poster #1001, titled "Rapid Discovery of High-Affinity, Human Antibodies Against 17 Immuno-Oncology Targets Using Molecular Genomic Screening Methods," from 7:30-10 p.m. PST on Monday, Feb. 26, at the Whistler Conference Centre in Whistler, British Columbia.
The Keystone Symposia on Molecular and Cellular Biology is a nonprofit organization that convenes a series of peer-reviewed conferences throughout the year on a broad range of life science disciplines, with the goal of serving as a catalyst for biomedical advancement.
About GigaGen GigaGen is a privately-held, preclinical biopharmaceutical company developing novel antibody therapies to treat diseases of immune dysregulation. GigaGen's deep understanding of immune dysregulation is enabled by industry-leading technology that quickly captures the genetic makeup of entire immune repertoires to analyze B cells at a rate of millions per hour, while simultaneously identifying their antigen and protein binders. GigaGen has a robust internal pipeline consisting of novel antibodies against immuno-oncology targets, in addition to the first recombinant intravenous immunoglobulin (IVIG) for patients with immune deficiency. For more information visit www.GigaGen.com.
China Jo-Jo Drugstores, Inc. ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced that it has entered...
MyFitnessPal, the #1 global nutrition and food tracking app, today announced that it has appointed Tim Holley as Chief Product Officer. In this role, Tim will apply his extensive experience driving sustained growth through reliable delivery of...
MDI Health, an AI-powered solution that optimizes personalized medication management at scale, announced that it has been selected as winner of the "Best New Technology Solution for Medication Management" award in the 8th annual MedTech Breakthrough...
Lumenis Be Ltd., a leading energy-based medical device company for aesthetic and eye care applications, announced today that triLift is the winner of the highly competitive "Best New Dermatology Technology Solution" award in the 8th annual MedTech...
Helius Medical Technologies, Inc. ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its first quarter 2024...
Medtech Canada, the national association representing Canada's medical technology companies, is very pleased to welcome James Brodie of Johnson & Johnson MedTech as Chair of the Medtech Canada Board of Directors. He is joined by five new board...